A preliminary large late-stage clinical trial has shown Moderna’s COVID-19 vaccine candidate is 94.5% effective in preventing COVID-19 and has no significant safety concerns, according to the company’s press release. The Phase 3 COVE Study enrolled more than 30,000 U.S. participants and was based on 95 cases, 90 of which were observed in the placebo group and 5 cases in the mRNA-1273 group.
- Moderna is expected to seek emergency-use authorization from the U.S. Food and Drug Administration if a further study shows their vaccines are safe.
- Moderna expects emergency authorization based on final analysis later this month involving 151 cases, along with two months of safety follow-up data.
- The vaccine prevents virtually all symptomatic cases of COVID-19.
- Moderna has indicated that there were no severe cases among people who got the vaccine, compared with 11 in volunteers who received placebo shots.
- Moderna’s vaccine is stable at refrigerator temperatures for 30 days, higher than previously estimated seven days.
- Moderna’s vaccine comes after Pfizer and BioNTech SE launched a vaccine candidate that was 90% effective.
Moderna’s stock is gaining on vaccine news. MRNA: NASDAQ is up 14.11% on premarket
